FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 360:1899-1901 April 30, 2009 Number 18 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by McHutchison, J. G. Related Article by Hézode, C. PubMed Citation

The therapy of hepatitis C began almost 25 years ago with a small trial of recombinant human interferon alfa.¹ The rationale for using interferon was its broad antiviral effects and the suspicion that it might be active against the still-undiscovered agent of non-A, non-B hepatitis. Indeed, interferon had striking effects, lowering serum aminotransferase levels and, in a proportion of patients, inducing a lasting improvement in serum enzyme levels. Not until the discovery of the hepatitis C virus (HCV) were the effects of interferon understood; treatment resulted in a decrease in HCV RNA levels, which led to a sustained absence of . . . [Full Text of this Article]

Source Information

From the Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD.

Related Letters:

Telaprevir for Chronic HCV Infection
van der Meer A. J.P., de Knegt R. J., Kao J.-H., McHutchison J., Pawlotsky J.-M., Zeuzem S., the PROVE1 and PROVE2 Study Teams
Extract | Full Text | PDF  
N Engl J Med 2009; 361:533-535, Jul 30, 2009. Correspondence

This article has been cited by other articles:

• van der Meer, A. J.P., de Knegt, R. J., Kao, J.-H., McHutchison, J., Pawlotsky, J.-M., Zeuzem, S., the PROVE1 and PROVE2 Study Teams, (2009). Telaprevir for Chronic HCV Infection. NEJM 361: 533-535 [Full Text]  
• (2009). Telaprevir Shows Promise for HCV, but Concerns Remain. JWatch Gastroenterology 2009: 1-1 [Full Text]